Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own0.30% Shs Outstand60.22M Perf Week13.09%
Market Cap421.54M Forward P/E- EPS next Y-0.41 Insider Trans20.71% Shs Float59.69M Perf Month7.36%
Income-37.50M PEG- EPS next Q-0.17 Inst Own99.20% Short Float11.50% Perf Quarter36.99%
Sales8.00M P/S52.69 EPS this Y27.50% Inst Trans1.67% Short Ratio16.35 Perf Half Y62.41%
Book/sh0.46 P/B15.22 EPS next Y43.10% ROA-71.80% Target Price12.14 Perf Year37.80%
Cash/sh1.17 P/C5.96 EPS next 5Y- ROE- 52W Range3.84 - 7.49 Perf YTD47.68%
Dividend- P/FCF- EPS past 5Y36.70% ROI-268.60% 52W High-6.54% Beta2.41
Dividend %- Quick Ratio1.90 Sales past 5Y8.20% Gross Margin- 52W Low82.29% ATR0.32
Employees32 Current Ratio1.90 Sales Q/Q0.00% Oper. Margin- RSI (14)71.49 Volatility5.89% 5.29%
OptionableYes Debt/Eq0.62 EPS Q/Q-13.00% Profit Margin- Rel Volume1.91 Prev Close6.78
ShortableYes LT Debt/Eq0.26 EarningsJul 29 Payout- Avg Volume419.79K Price7.00
Recom1.80 SMA2012.50% SMA5018.81% SMA20028.88% Volume789,700 Change3.24%
12-Jun-14Initiated UBS Buy $14
11-Sep-12Reiterated Cantor Fitzgerald Buy $6 → $8
29-May-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
13-Apr-12Initiated Cantor Fitzgerald Buy $6
06-Mar-12Initiated Canaccord Genuity Buy $4
11-Oct-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
29-Sep-11Initiated MLV Capital Buy $3.50
29-Jul-14 07:00AM  Sunesis to Host Conference Call on August 5th to Discuss Second Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
14-Jul-14 05:45PM  Sunesis' Pediatric Plan Accepted in the EU Zacks
09-Jul-14 08:42AM  Better Buy: Clovis Oncology vs. Sunesis Pharmaceuticals at Motley Fool
07:04AM  Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo For AML Benzinga
07:00AM  Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo(TM) (Vosaroxin) for AML GlobeNewswire
13-Jun-14 07:11AM  Sunesis Pharmaceuticals (SNSS) Soars: Stock Adds 8% in Session Zacks
07:11AM  Sunesis Pharmaceuticals (SNSS) Soars: Stock Adds 8% in Session
12-Jun-14 02:00PM  Coverage initiated on Sunesis Pharma by UBS Briefing.com +7.96%
02:00PM  Coverage initiated on Sunesis Pharma by UBS
09:13AM  On The Fly: Pre-market Movers at theflyonthewall.com
11-Jun-14 07:00AM  Sunesis to Present at the 2014 Wells Fargo Healthcare Conference GlobeNewswire
07:00AM  Sunesis to Present at the 2014 Wells Fargo Healthcare Conference
09-Jun-14 04:24PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
04:24PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
02-Jun-14 07:16AM  Sunesis says encouraged by trial of Qinprezo at theflyonthewall.com
07:16AM  Sunesis says encouraged by trial of Qinprezo
07:00AM  Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASCO 2014 Annual Meeting GlobeNewswire
07:00AM  Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASCO 2014 Annual Meeting
16-May-14 01:04PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials
01:04PM  SUNESIS PHARMACEUTICALS INC Financials
14-May-14 07:00AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
07:00AM  Sunesis to Present at Upcoming Investor Conferences
09-May-14 11:14AM  Sunesis Pharmaceuticals Inc Stock Downgraded (SNSS) at TheStreet +5.25%
11:14AM  Sunesis Pharmaceuticals Inc Stock Downgraded (SNSS)
08-May-14 06:52AM  Is Sunesis Pharmaceuticals Poised for a Breakout? at Motley Fool
06:52AM  Is Sunesis Pharmaceuticals Poised for a Breakout?
07-May-14 02:00PM  Sunesis Pharmaceuticals' (SNSS) CEO Daniel Swisher on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
10:49AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
08:03AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:34AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
07:07AM  Q1 2014 Sunesis Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
30-Apr-14 07:00AM  Sunesis to Host Conference Call on May 7th to Discuss First Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
29-Apr-14 06:31PM  3 Ways Ariad Pharmaceuticals Could Mount a Comeback at Motley Fool
22-Apr-14 07:00AM  Sunesis Announces MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Poster to be Presented at ASCO 2014 GlobeNewswire +8.16%
10-Apr-14 06:31PM  2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals at Motley Fool -8.75%
08-Apr-14 01:30PM  Sunesis vosaroxin shown to be effective, says Wedbush at theflyonthewall.com
11:00AM  Sunesis Pharmaceuticals Update Call to Discuss Poster Presented at the AACR Annual Meeting scheduled for 11:00 am ET today CCBN
11:00AM  SS&C Technologies Earnings Call scheduled for 11:00 am ET today CCBN
08:00AM  Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS GlobeNewswire
07-Apr-14 11:17AM  Is Now the Time to Invest in Agios Pharmaceuticals, Inc? at Motley Fool
02-Apr-14 07:00AM  Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014 GlobeNewswire +5.02%
31-Mar-14 07:04PM  Nasdaq stocks posting largest percentage decreases AP +5.93%
01:47PM  Nasdaq stocks posting largest percentage decreases AP
28-Mar-14 06:02PM  Nasdaq stocks posting largest percentage decreases AP -8.24%
24-Mar-14 04:03PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
12-Mar-14 01:04PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials
06-Mar-14 02:40PM  Sunesis Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
02:40PM  Sunesis Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
08:03AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q4 2013 Sunesis Pharmaceuticals, Inc. Earnings Release - Time Not Supplied CCBN
07:00AM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights GlobeNewswire
05-Mar-14 07:46AM  Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher Zacks
07:46AM  Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher
04-Mar-14 01:04PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials +6.76%
28-Feb-14 04:52PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:18AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
08:17AM  Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights GlobeNewswire
27-Feb-14 06:42PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
08:44AM  Sunesis raises $43M in common stock and warrants offering theflyonthewall.com
08:30AM  Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants GlobeNewswire
26-Feb-14 04:13PM  Sunesis Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire +5.33%
01:51PM  Nasdaq stocks posting largest percentage increases AP
25-Feb-14 06:02PM  Nasdaq stocks posting largest percentage increases AP +17.46%
01:28PM  Nasdaq stocks posting largest percentage increases AP
07:49AM  Sunesis risk/reward attractive at current levels, says Leerink theflyonthewall.com
19-Feb-14 04:01AM  3 Small Cap Biotechs Developing Novel Cancer Treatments at Motley Fool
11-Feb-14 07:33AM  Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% Zacks
10-Feb-14 08:01AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -5.42%
07:26AM  Sunesis announces vosaroxin Phase 3 VALOR trial unblinding expected in Q3 theflyonthewall.com
07:15AM  Sunesis (SNSS) Catches Eye: Stock Soars 18.3% Zacks
07:00AM  Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data GlobeNewswire
06-Feb-14 07:24AM  Sunesis Pharmaceuticals (SNSS) Sees Hammer Chart Pattern: Time to Buy? Zacks
07:05AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
17-Jan-14 03:52PM  Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week at TheStreet
09-Jan-14 11:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise Call scheduled for 11:00 am ET today CCBN
11:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise Call scheduled for 11:00 am ET today
11:00AM  Ingredion Incorporated Earnings Call scheduled for 11:00 am ET today CCBN
08:14AM  Sunesis Pharmaceuticals Expands Hematology Franchise Call scheduled for 11:00 am ET today CCBN
07:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs GlobeNewswire
07:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs
26-Dec-13 01:47AM  Idenix Pharmaceuticals (IDIX) Soars: Stock Adds 18.2% in Session Zacks
01:47AM  Idenix Pharmaceuticals (IDIX) Soars: Stock Adds 18.2% in Session
17-Dec-13 07:33AM  Sunesis Pharmaceuticals, Inc. is now in Oversold Territory Zacks
07:33AM  Sunesis Pharmaceuticals, Inc. is now in Oversold Territory
10-Dec-13 07:00AM  Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS GlobeNewswire
07:00AM  Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS
03-Dec-13 10:38PM  Sunesis Pharmaceuticals' CEO Presents at the Piper Jaffray Healthcare Conference 2013 at Seeking Alpha
10:38PM  Sunesis Pharmaceuticals' CEO Presents at the Piper Jaffray Healthcare Conference 2013
27-Nov-13 07:00AM  Sunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference GlobeNewswire
07:00AM  Sunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference
20-Nov-13 01:05PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials
01:05PM  SUNESIS PHARMACEUTICALS INC Financials
12-Nov-13 03:20PM  Sunesis Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
03:20PM  Sunesis Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today
10:55AM  Sunesis Pharmaceuticals, Inc. Discusses Q3 2013 Results (Webcast) at Seeking Alpha
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of PDK1. The company was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swisher Daniel N JRPresident and CEOMay 16Option Exercise2.0924,38950,973152,406May 19 05:11 PM
Ketchum Steven BDirectorNov 08Option Exercise2.0910,50321,95184,464Apr 02 07:29 PM
Ketchum Steven BDirectorNov 08Sale5.0810,50353,36473,961Apr 02 07:29 PM
Ketchum Steven BDirectorNov 07Option Exercise2.0919,55140,86293,512Apr 02 07:29 PM
Ketchum Steven BDirectorNov 07Sale5.0319,55198,29573,961Apr 02 07:29 PM